tiprankstipranks
Advertisement
Advertisement

HK:1672 Stock Latest News

Ascletis files U.S. INDs for next‑generation monthly obesity injections
Company AnnouncementsAscletis files U.S. INDs for next‑generation monthly obesity injections
9d ago
1672
Ascletis Pharma Launches HK$300 Million Share Buyback Under Mandate
PremiumCompany Announcements
Ascletis Pharma Launches HK$300 Million Share Buyback Under Mandate
15d ago
1672
Ascletis Pharma Wins Shareholder Backing for All AGM Resolutions and Capital Mandates
PremiumCompany Announcements
Ascletis Pharma Wins Shareholder Backing for All AGM Resolutions and Capital Mandates
16d ago
1672
Ascletis Wins FDA Green Light for Monthly Obesity Drug ASC35 Phase I Trial
PremiumCompany Announcements
Ascletis Wins FDA Green Light for Monthly Obesity Drug ASC35 Phase I Trial
22d ago
1672
Ascletis Showcases Differentiated Oral Obesity Drugs at ADA 2026
PremiumCompany Announcements
Ascletis Showcases Differentiated Oral Obesity Drugs at ADA 2026
1M ago
1672
Ascletis Pharma Sets 2026 AGM and Seeks Renewal of Share Issuance Mandate
PremiumCompany AnnouncementsAscletis Pharma Sets 2026 AGM and Seeks Renewal of Share Issuance Mandate
1M ago
1672
Ascletis Pharma Seeks Shareholder Approval to Modernize Governance Rules
Premium
Company Announcements
Ascletis Pharma Seeks Shareholder Approval to Modernize Governance Rules
1M ago
1672
Ascletis to Showcase Promising Obesity Drug Pipeline at ECO 2026
Premium
Company Announcements
Ascletis to Showcase Promising Obesity Drug Pipeline at ECO 2026
2M ago
1672
Ascletis to Unveil Obesity and Metabolic Drug Data at ADA 2026
PremiumCompany Announcements
Ascletis to Unveil Obesity and Metabolic Drug Data at ADA 2026
3M ago
1672
Ascletis Completes U.S. Phase II Enrollment for Oral GLP-1 Diabetes Drug ASC30
PremiumCompany Announcements
Ascletis Completes U.S. Phase II Enrollment for Oral GLP-1 Diabetes Drug ASC30
3M ago
1672
Ascletis Advances Fixed-Dose Oral Obesity Pill Toward U.S. FDA IND in 2026
PremiumCompany Announcements
Ascletis Advances Fixed-Dose Oral Obesity Pill Toward U.S. FDA IND in 2026
3M ago
1672
Ascletis Deepens R&D Push in Obesity Drugs as 2025 Loss Widens
PremiumCompany Announcements
Ascletis Deepens R&D Push in Obesity Drugs as 2025 Loss Widens
4M ago
1672
Ascletis Pharma Sets March 31 Board Meeting to Approve 2025 Results and Consider Dividend
PremiumCompany AnnouncementsAscletis Pharma Sets March 31 Board Meeting to Approve 2025 Results and Consider Dividend
4M ago
1672
Ascletis Advances Oral Amylin Agonist ASC39 Toward U.S. IND for Obesity
Premium
Company Announcements
Ascletis Advances Oral Amylin Agonist ASC39 Toward U.S. IND for Obesity
4M ago
1672
Ascletis Posts Positive U.S. Phase II Data for Monthly GLP-1 Obesity Drug ASC30
Premium
Company Announcements
Ascletis Posts Positive U.S. Phase II Data for Monthly GLP-1 Obesity Drug ASC30
4M ago
1672
Ascletis Advances Oral Amylin Obesity Drug ASC36 Toward U.S. Clinical Trials
PremiumCompany Announcements
Ascletis Advances Oral Amylin Obesity Drug ASC36 Toward U.S. Clinical Trials
5M ago
1672
Ascletis Raises HK$835 Million to Fund Global Phase III Obesity Drug Trials
PremiumCompany Announcements
Ascletis Raises HK$835 Million to Fund Global Phase III Obesity Drug Trials
5M ago
1672
Ascletis Pharma to Raise HK$835 Million via Share Placement to Fund Obesity Drug Trials
PremiumCompany Announcements
Ascletis Pharma to Raise HK$835 Million via Share Placement to Fund Obesity Drug Trials
5M ago
1672
Ascletis Reports Positive Long-Term Phase III Safety Data for First-in-Class Oral Acne Drug Denifanstat
PremiumCompany Announcements
Ascletis Reports Positive Long-Term Phase III Safety Data for First-in-Class Oral Acne Drug Denifanstat
6M ago
1672
Ascletis Starts U.S. Phase II Diabetes Trial of Oral GLP-1 Drug ASC30 After Strong Obesity Data
PremiumCompany AnnouncementsAscletis Starts U.S. Phase II Diabetes Trial of Oral GLP-1 Drug ASC30 After Strong Obesity Data
6M ago
1672
Ascletis Advances Next-Generation Once-Monthly Triple Agonist ASC37 for Obesity Into Clinical Pathway
Premium
Company Announcements
Ascletis Advances Next-Generation Once-Monthly Triple Agonist ASC37 for Obesity Into Clinical Pathway
6M ago
1672
Ascletis Wins FDA Green Light for Phase II U.S. Diabetes Trial of Oral GLP-1 Drug ASC30
Premium
Company Announcements
Ascletis Wins FDA Green Light for Phase II U.S. Diabetes Trial of Oral GLP-1 Drug ASC30
6M ago
1672

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >